Michael Gelband’s Takeda Pharmaceutical TAK Stock Holding History

Michael Gelband’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,285	Closed	-$209K	–	2132
2023 Q2	$209K	Sell	13,285 -16,420	-55%	-$269K	﹤0.01%	1666
2023 Q1	$490K	Sell	29,705 -146	-0.5%	-$2.33K	﹤0.01%	1342
2022 Q4	$466K	Buy	+29,851	New	+$417K	0.01%	1201
2022 Q3	–	Sell	-23,779	Closed	-$334K	–	2290
2022 Q2	$334K	Sell	23,779 -8,063	-25%	-$115K	﹤0.01%	1492
2022 Q1	$456K	Sell	31,842 -26,414	-45%	-$388K	0.01%	1585
2021 Q4	$794K	Buy	58,256 +26,063	+81%	+$366K	0.01%	1187
2021 Q3	$527K	Buy	+32,193	New	+$540K	0.01%	1345
2021 Q2	–	Sell	-31,363	Closed	-$573K	–	2789
2021 Q1	$573K	Sell	31,363 -10,372	-25%	-$187K	0.01%	1250
2020 Q4	$760K	Buy	41,735 +10,450	+33%	+$183K	0.01%	1006
2020 Q3	$558K	Buy	+31,285	New	+$570K	0.01%	957
2020 Q1	–	Sell	-25,506	Closed	-$503K	–	1622
2019 Q4	$503K	Buy	+25,506	New	+$488K	0.01%	852

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's TAK Position: Q3 2023 in Review

Michael Gelband sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 13,285 shares — an estimated $209K sold.

Michael Gelband first reported a position in TAK in Q4 2019 and held it in 11 quarters. The position peaked at $794K in Q4 2021. 313 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Michael Gelband reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Michael Gelband sold 13,285 Takeda Pharmaceutical shares in Q3 2023, an estimated $209K.
Michael Gelband first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 11 quarters.
Michael Gelband's Takeda Pharmaceutical position peaked at $794K in Q4 2021.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.